CA3063715A1 - Combination therapies for treating cancer - Google Patents
Combination therapies for treating cancer Download PDFInfo
- Publication number
- CA3063715A1 CA3063715A1 CA3063715A CA3063715A CA3063715A1 CA 3063715 A1 CA3063715 A1 CA 3063715A1 CA 3063715 A CA3063715 A CA 3063715A CA 3063715 A CA3063715 A CA 3063715A CA 3063715 A1 CA3063715 A1 CA 3063715A1
- Authority
- CA
- Canada
- Prior art keywords
- agent
- cancer
- macrophage
- group
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762508363P | 2017-05-18 | 2017-05-18 | |
| US62/508,363 | 2017-05-18 | ||
| US201762508481P | 2017-05-19 | 2017-05-19 | |
| US62/508,481 | 2017-05-19 | ||
| US201762578204P | 2017-10-27 | 2017-10-27 | |
| US62/578,204 | 2017-10-27 | ||
| PCT/US2018/033437 WO2018213732A1 (en) | 2017-05-18 | 2018-05-18 | Combination therapies for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3063715A1 true CA3063715A1 (en) | 2018-11-22 |
Family
ID=62705671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3063715A Pending CA3063715A1 (en) | 2017-05-18 | 2018-05-18 | Combination therapies for treating cancer |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11622961B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3624850A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2020520921A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20200005662A (cg-RX-API-DMAC7.html) |
| CN (1) | CN110913911A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2018270112A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019024135A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3063715A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL270720A (cg-RX-API-DMAC7.html) |
| MA (1) | MA49144A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019013755A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018213732A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116370607A (zh) * | 2023-03-20 | 2023-07-04 | 中国人民解放军陆军军医大学第一附属医院 | 人重组hmgb1在制备治疗胶质瘤化疗增敏剂中的应用 |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| PE20171094A1 (es) | 2014-12-04 | 2017-08-07 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda |
| CR20170526A (es) | 2015-05-20 | 2018-04-03 | Janssen Biotech Inc | ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38 |
| JP7027321B2 (ja) | 2015-11-03 | 2022-03-01 | ヤンセン バイオテツク,インコーポレーテツド | 抗cd38抗体の皮下製剤及びその使用 |
| WO2018002181A1 (en) | 2016-06-28 | 2018-01-04 | Umc Utrecht Holding B.V. | TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38 |
| AU2018246214B2 (en) | 2017-03-27 | 2021-07-08 | Merck Sharp & Dohme Llc | Niraparib compositions |
| WO2018200517A1 (en) | 2017-04-24 | 2018-11-01 | Tesaro, Inc. | Methods of manufacturing of niraparib |
| TW202444417A (zh) | 2017-05-09 | 2024-11-16 | 美商提薩羅有限公司 | 治療癌症的組合療法 |
| CN110913911A (zh) | 2017-05-18 | 2020-03-24 | 特沙诺有限公司 | 用于治疗癌症的组合疗法 |
| CN111278433A (zh) | 2017-09-26 | 2020-06-12 | 特沙诺有限公司 | 尼拉帕尼制剂 |
| WO2019067978A1 (en) | 2017-09-30 | 2019-04-04 | Tesaro, Inc. | POLYTHERAPIES FOR THE TREATMENT OF CANCER |
| US11801240B2 (en) | 2017-10-06 | 2023-10-31 | Tesaro, Inc. | Combination therapies and uses thereof |
| BR112020015909A2 (pt) * | 2018-02-05 | 2020-12-15 | Tesaro, Inc. | Formulações pediátricas de niraparib e métodos de tratamento pediátrico |
| EP3846855B1 (en) * | 2018-09-04 | 2024-12-04 | Pfizer Inc. | Cd47 blockade with parp inhibition for disease treatment |
| US12297184B2 (en) | 2018-10-03 | 2025-05-13 | Tesaro, Inc. | Niraparib salts |
| US20220128544A1 (en) * | 2019-02-13 | 2022-04-28 | Creatv Microtech, Inc. | Ccr5-based methods for predicting overall and progression free survival in subjects having cancer |
| EP3966782A2 (en) | 2019-05-06 | 2022-03-16 | Tesaro, Inc. | Methods for characterizing and treating a cancer type using cancer images |
| CN112870365A (zh) * | 2019-11-29 | 2021-06-01 | 江苏恒瑞医药股份有限公司 | Ezh2抑制剂和/或parp抑制剂与化疗药物联合在制备治疗肿瘤药物中的用途 |
| CA3168493A1 (en) * | 2020-02-20 | 2021-08-26 | The Royal Institution For The Advancement Of Learning/Mcgill University | Use of castalagin or analogs thereof for anti-cancer efficacy and to increase the response to immune checkpoint inhibitors |
| US20240016775A1 (en) * | 2020-02-24 | 2024-01-18 | Fukang (Shanghai) Health Technology Co., Ltd | Anti-coronavirus application of poly adp ribose polymerase inhibitor |
| US20230123585A1 (en) * | 2020-03-03 | 2023-04-20 | The University Of Chicago | Compositions and methods for treating or preventing cancer using deubiquitinase inhibitors |
| TWI877433B (zh) * | 2020-11-30 | 2025-03-21 | 大陸商杭州阿諾生物醫藥科技有限公司 | 用於治療pik3ca突變癌症的組合療法 |
| WO2022173932A1 (en) * | 2021-02-11 | 2022-08-18 | Dana-Farber Cancer Institute, Inc. | Methods of treating cancers using sting agonists |
| US20220275090A1 (en) * | 2021-02-22 | 2022-09-01 | Janssen Biotech, Inc. | Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors |
| EP4314036A1 (en) * | 2021-03-25 | 2024-02-07 | T3 Pharmaceuticals AG | Pharmaceutical combinations for treating cancer |
| MA62924A1 (fr) * | 2021-04-08 | 2024-03-29 | Biocad Joint Stock Co | Traitement de néoplasies malignes à l'aide d'une combinaison d'anticorps anti-pd-1 |
| EP4323001A4 (en) * | 2021-04-11 | 2025-03-05 | Adagene Inc. | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER |
| WO2022271547A1 (en) | 2021-06-21 | 2022-12-29 | Tesaro, Inc. | Combination treatment of cancer with a parp inhibitor and a lipophilic statin |
| WO2023048506A1 (ko) * | 2021-09-23 | 2023-03-30 | 국립암센터 | 카르니틴 아실카르니틴 운반자 억제제 및 항암제를 포함하는 암 예방 또는 치료용 약학적 조성물 |
| WO2023088436A1 (zh) * | 2021-11-18 | 2023-05-25 | 信达生物制药(苏州)有限公司 | 抗pd-1抗体和抗vegf-a抗体的药物组合及其使用方法 |
| US20250073234A1 (en) * | 2022-01-04 | 2025-03-06 | Cornell University | Combination therapies including parp1 inhibitors |
| US20250352534A1 (en) | 2022-02-15 | 2025-11-20 | Tesaro, Inc. | Use of Niraparib for the Treatment of Brain Cancer |
| CN116694568A (zh) * | 2022-03-02 | 2023-09-05 | 北京市希波生物医学技术有限责任公司 | 用于激活整体抗肿瘤免疫系统的培养基配方物及制备激动剂激活的整体免疫效应细胞的方法 |
| CN117462687A (zh) * | 2022-07-20 | 2024-01-30 | 清华大学 | 一种用于制备预防或治疗骨转移癌药物的组合物及其应用 |
| WO2024216089A1 (en) * | 2023-04-13 | 2024-10-17 | Bolt Biotherapeutics, Inc. | Anti-dectin-2 antibody combination therapy |
| CN118718000A (zh) * | 2023-06-19 | 2024-10-01 | 上海市第六人民医院 | 药物组合物及其在制备治疗肾癌的药物中的用途 |
| CN116726187B (zh) * | 2023-07-26 | 2025-09-30 | 珠海市人民医院 | 一种小分子配体-鲁卡帕尼偶联物及其制备方法 |
| WO2025225834A1 (ko) * | 2024-04-25 | 2025-10-30 | 한국 한의학 연구원 | 루카파립 캄실레이트를 유효성분으로 함유하는 항암제 내성암의 예방 또는 치료용 약학 조성물 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2059571T3 (es) | 1988-01-19 | 1994-11-16 | Takeda Chemical Industries Ltd | Fumagilina como agente angiostatico. |
| DE68915900T2 (de) | 1988-09-01 | 1994-11-24 | Childrens Medical Center | Angiogenese hemmendes Mittel. |
| DE60334303D1 (de) | 2002-07-03 | 2010-11-04 | Tasuku Honjo | Immunpotenzierende zusammensetzungen |
| US9707302B2 (en) | 2013-07-23 | 2017-07-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| US20090275619A1 (en) | 2006-04-03 | 2009-11-05 | BOUERES Julia | Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors |
| BRPI0806245B1 (pt) | 2007-01-10 | 2022-01-25 | Msd Italia S.R.L. | Compostos de fórmula i e seus usos |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| AU2008321382A1 (en) | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of uterine cancer and ovarian cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
| WO2009064738A2 (en) | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| EP2240466B1 (en) | 2008-01-08 | 2015-07-29 | Merck Sharp & Dohme Limited | Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide |
| US9078864B2 (en) | 2008-01-08 | 2015-07-14 | Akthelia Pharmaceuticals | Agonists for antimicrobial peptide systems |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| AR075239A1 (es) | 2009-02-04 | 2011-03-16 | Bipar Sciences Inc | Tratamiento del cancer de pulmon con un inhibidor de la parp en combinacion con un inhibidor de un factor de crecimiento. composicion farmaceutica. uso |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| WO2011153383A1 (en) | 2010-06-04 | 2011-12-08 | Bipar Science, Inc. | Methods of treating platinum-resistant recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and a platinum compound |
| EP3327148B1 (en) | 2010-06-18 | 2021-03-17 | Myriad Genetics, Inc. | Methods of predicting the status of brca1 and brca2 genes in a cancer cell |
| ES2704303T3 (es) | 2010-08-24 | 2019-03-15 | Dana Farber Cancer Inst Inc | Procedimientos para la predicción de una respuesta contra el cáncer |
| CA2742342A1 (en) | 2011-02-12 | 2012-08-12 | Baylor Research Institute | Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| CA2867434C (en) | 2012-06-07 | 2021-10-12 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| EP2928473B1 (en) | 2012-12-07 | 2017-06-28 | Merck Sharp & Dohme Corp. | Regioselective n-2 arylation of indazoles |
| DK2928865T3 (en) | 2012-12-07 | 2018-06-18 | Merck Sharp & Dohme | BIOCATALYTIC TRANSAMINATION PROCEDURE |
| WO2014138101A1 (en) | 2013-03-04 | 2014-09-12 | Board Of Regents, The University Of Texas System | Gene signature to predict homologous recombination (hr) deficient cancer |
| US20150071910A1 (en) | 2013-03-15 | 2015-03-12 | Genentech, Inc. | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
| RS61400B1 (sr) | 2013-05-02 | 2021-02-26 | Anaptysbio Inc | Antitela usmerena protiv programirane smrti-1 (pd-1) |
| CA2931181C (en) | 2013-12-09 | 2023-01-24 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| JP6663350B2 (ja) | 2014-01-16 | 2020-03-11 | クロヴィス・オンコロジー,インコーポレーテッド | ヘテロ接合性の喪失を示す乳癌または卵巣癌の患者を治療するためのparp阻害剤の使用 |
| US20170175197A1 (en) | 2014-01-29 | 2017-06-22 | Caris Mpi, Inc. | Molecular profiling of immune modulators |
| JP6648040B2 (ja) | 2014-05-28 | 2020-02-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | がん治療のための併用療法としてのエリブリン及びポリ(adpリボース)ポリメラーゼ(parp)阻害剤の使用 |
| US20150344968A1 (en) | 2014-05-30 | 2015-12-03 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Methods for determining parp inhibitor and platinum resistance in cancer therapy |
| US20160160294A1 (en) | 2014-12-08 | 2016-06-09 | Tesaro | Methods and materials for predicting response to niraparib |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| PL3277321T3 (pl) | 2015-04-01 | 2024-11-18 | Anaptysbio, Inc. | Przeciwciała skierowane przeciwko białku 3 immunoglobuliny limfocytów t i mucyny (tim-3) |
| WO2016176503A1 (en) | 2015-04-28 | 2016-11-03 | Bristol-Myers Squibb Company | Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody |
| EP3303397A1 (en) | 2015-06-08 | 2018-04-11 | H. Hoffnabb-La Roche Ag | Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists |
| PT3313443T (pt) | 2015-06-25 | 2023-08-30 | Immunomedics Inc | Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro |
| SG10201913073YA (en) | 2015-08-20 | 2020-03-30 | Ipsen Biopharm Ltd | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
| CN108883115A (zh) | 2015-10-26 | 2018-11-23 | 麦迪韦逊科技有限责任公司 | 用parp抑制剂治疗小细胞肺癌 |
| WO2017142871A1 (en) | 2016-02-15 | 2017-08-24 | Astrazeneca Ab | Methods comprising fixed intermittent dosing of cediranib |
| HRP20240136T1 (hr) | 2016-06-29 | 2024-04-12 | Tesaro, Inc. | Metode liječenja raka jajnika |
| US11202782B2 (en) | 2016-09-27 | 2021-12-21 | Beigene, Ltd. | Treatment cancers using a combination comprising PARP inhibitors |
| MA50677A (fr) | 2016-11-01 | 2021-07-14 | Anaptysbio Inc | Anticorps dirigés contre la protéine d'immunoglobuline de lymphocytes t et mucine 3 (tim-3) |
| CN110049777A (zh) | 2016-11-01 | 2019-07-23 | 安奈普泰斯生物有限公司 | 针对程序性死亡-1(pd-1)的抗体 |
| AU2018205401B2 (en) | 2017-01-09 | 2025-01-02 | Tesaro, Inc. | Methods of treating cancer with anti-TIM-3 antibodies |
| PT3565844T (pt) | 2017-01-09 | 2023-05-02 | Tesaro Inc | Métodos de tratamento de cancro com anticorpos anti-pd-1 |
| AU2018246214B2 (en) | 2017-03-27 | 2021-07-08 | Merck Sharp & Dohme Llc | Niraparib compositions |
| EP3606523A1 (en) | 2017-03-27 | 2020-02-12 | Tesaro, Inc. | Niraparib formulations |
| WO2018200517A1 (en) | 2017-04-24 | 2018-11-01 | Tesaro, Inc. | Methods of manufacturing of niraparib |
| TWI791519B (zh) | 2017-04-27 | 2023-02-11 | 美商提薩羅有限公司 | 針對淋巴細胞活化基因-3(lag-3)之抗體藥劑及其用途 |
| TW202444417A (zh) | 2017-05-09 | 2024-11-16 | 美商提薩羅有限公司 | 治療癌症的組合療法 |
| CN110913911A (zh) | 2017-05-18 | 2020-03-24 | 特沙诺有限公司 | 用于治疗癌症的组合疗法 |
| US20200129482A1 (en) | 2017-06-26 | 2020-04-30 | Abbvie Inc. | Treatment of non-small cell lung cancer |
| CN111278433A (zh) | 2017-09-26 | 2020-06-12 | 特沙诺有限公司 | 尼拉帕尼制剂 |
| WO2019067978A1 (en) | 2017-09-30 | 2019-04-04 | Tesaro, Inc. | POLYTHERAPIES FOR THE TREATMENT OF CANCER |
| US11801240B2 (en) | 2017-10-06 | 2023-10-31 | Tesaro, Inc. | Combination therapies and uses thereof |
| TW201929902A (zh) | 2017-12-27 | 2019-08-01 | 美商提薩羅有限公司 | 治療癌症之方法 |
| BR112020015909A2 (pt) | 2018-02-05 | 2020-12-15 | Tesaro, Inc. | Formulações pediátricas de niraparib e métodos de tratamento pediátrico |
| EA201992594A1 (ru) | 2018-03-26 | 2020-03-20 | Тесаро, Инк. | Комбинированные терапии для лечения рака |
| US11970530B2 (en) | 2020-08-13 | 2024-04-30 | Astrazeneca Ab | Methods of treating homologous recombination deficient cancer |
-
2018
- 2018-05-18 CN CN201880047169.9A patent/CN110913911A/zh active Pending
- 2018-05-18 MX MX2019013755A patent/MX2019013755A/es unknown
- 2018-05-18 KR KR1020197037232A patent/KR20200005662A/ko not_active Ceased
- 2018-05-18 AU AU2018270112A patent/AU2018270112A1/en not_active Abandoned
- 2018-05-18 US US16/614,131 patent/US11622961B2/en active Active
- 2018-05-18 BR BR112019024135-3A patent/BR112019024135A2/pt not_active IP Right Cessation
- 2018-05-18 WO PCT/US2018/033437 patent/WO2018213732A1/en not_active Ceased
- 2018-05-18 MA MA049144A patent/MA49144A/fr unknown
- 2018-05-18 CA CA3063715A patent/CA3063715A1/en active Pending
- 2018-05-18 EP EP18733393.5A patent/EP3624850A1/en not_active Withdrawn
- 2018-05-18 JP JP2019563582A patent/JP2020520921A/ja active Pending
-
2019
- 2019-11-17 IL IL270720A patent/IL270720A/en unknown
-
2021
- 2021-08-09 AU AU2021215113A patent/AU2021215113A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116370607A (zh) * | 2023-03-20 | 2023-07-04 | 中国人民解放军陆军军医大学第一附属医院 | 人重组hmgb1在制备治疗胶质瘤化疗增敏剂中的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| US11622961B2 (en) | 2023-04-11 |
| BR112019024135A2 (pt) | 2020-06-02 |
| US20210008053A1 (en) | 2021-01-14 |
| WO2018213732A1 (en) | 2018-11-22 |
| CN110913911A (zh) | 2020-03-24 |
| MA49144A (fr) | 2020-03-25 |
| AU2021215113A1 (en) | 2021-08-26 |
| IL270720A (en) | 2020-01-30 |
| MX2019013755A (es) | 2020-07-20 |
| KR20200005662A (ko) | 2020-01-15 |
| AU2018270112A1 (en) | 2019-12-12 |
| EP3624850A1 (en) | 2020-03-25 |
| JP2020520921A (ja) | 2020-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11622961B2 (en) | Combination therapies for treating cancer | |
| JP7717749B2 (ja) | 癌を治療するための併用療法 | |
| US11801240B2 (en) | Combination therapies and uses thereof | |
| EP4019019B1 (en) | Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers | |
| CN107801379B (zh) | 抗癌剂 | |
| CN110996952A (zh) | 用于治疗癌症的方法 | |
| CA3076515A1 (en) | Combination therapies for treating cancer | |
| JP7028765B2 (ja) | ベンズアミドおよび活性化合物組成物および使用方法 | |
| TW202231283A (zh) | 用於治療轉移性大腸直腸癌之經改良之基於氟尿嘧啶之多藥劑化學治療 | |
| KR20200112904A (ko) | 암을 치료하는 조성물 및 방법 | |
| KR20180006416A (ko) | 티로신 키나아제 억제제와 병용하여 egf/egfr 경로를 억제하는 방법 및 조성물 | |
| CN110234319B (zh) | 苯甲酰胺和活性化合物的组合物及其使用方法 | |
| JP2022534412A (ja) | プロカスパーゼ‐3の活性化及びがんの治療のための免疫療法 | |
| HK40075828B (en) | Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers | |
| HK40075828A (en) | Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers | |
| HK40007619A (en) | Benzamide and active compound compositions and methods of use | |
| HK40007619B (en) | Benzamide and active compound compositions and methods of use |